Advertisement
Advertisement
U.S. markets open in 7 hours 24 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Swisscanto AST Responsible Global Convertible CHF hedged NT CHF (0P00012DKE.SW)

Swiss - Swiss Delayed Price. Currency in CHF
127.12+0.33 (+0.26%)
At close: 09:00PM CET
Advertisement
Full screen
Previous Close126.79
YTD Return4.56%
Expense Ratio (net)0.00%
CategoryConvertible Bond - Global, CHF Hedged
Last Cap GainN/A
Morningstar Rating★★★★★
Morningstar Risk RatingN/A
Sustainability Rating
Net Assets39.04M
Beta (5Y Monthly)N/A
YieldN/A
5y Average ReturnN/A
Holdings TurnoverN/A
Last DividendN/A
Average for CategoryN/A
Inception DateApr 08, 2013
  • PR Newswire

    Provention Bio Announces the Grant of Inducement Awards

    Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to eight new employees to purchase an aggregate of 166,000 shares of common stock. The stock options were granted without stockholder approval as inducements, material to the new employees entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4) and were approved by t

  • PR Newswire

    Provention Bio to Present at the Jefferies Global Healthcare Conference

    Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a corporate presentation at the Jefferies Global Healthcare Conference on Wednesday, June 8th 2022 at 9:00 am EST in New York City.

  • PR Newswire

    Provention Bio Announces Update to Board of Directors

    Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced Dr. Jeffrey Bluestone's decision to step down as a director on the Company's board of directors to focus on his other commitments, including his role as President and Chief Executive Officer of Sonoma Biotherapeutics. Dr. Bluestone will continue as Scientific Advisor to the Company.

Advertisement
Advertisement